Therapeutic implant
View Patent ↗Surgical implants are provided which include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
1. A method of treating tissue comprising the steps of:
implanting in the tissue a surgical implant, the surgical implant comprising a rapidly degrading polymeric film comprising carboxymethylcellulose and glycerol combined at a ratio of 5:1 and a first therapeutic agent and a mesh coated with a second therapeutic agent; wherein the rapidly degrading polymeric film releases the first therapeutic agent to the tissue in less than 1 hour; and the mesh releases the second therapeutic agent to the tissue in greater than 24 hours after implantation.
2. The method according to claim 1 , wherein the first therapeutic agent is different than the second therapeutic agent.
3. The method according to claim 1 , wherein at least one of the first and the second therapeutic agent is selected from the group consisting of bupivacaine hydrochloride, bupivacaine, and capsaicin.
4. The method according to claim 1 , wherein the first therapeutic agent is bupivacaine hydrochloride.
5. The method according to claim 4 , wherein the second therapeutic agent is bupivacaine free base.
6. A method of treating tissue comprising the steps of:
implanting in the tissue a surgical implant, the surgical implant comprising a rapidly degrading polymeric film comprising carboxymethylcellulose and glycerol at a ratio of 5:1 and including a first therapeutic agent comprising a first form of bupivacaine and a mesh coated with a second therapeutic agent comprising a second form of bupivacaine which is different from the first form of bupivacaine; wherein the rapidly degrading polymeric film releases the first therapeutic agent to the tissue in less than 1 hour; and the mesh releases the second therapeutic agent to the tissue in greater than 24 hours after implantation.
7. The method according to claim 6 , wherein the first therapeutic agent is bupivacaine hydrochloride.
8. The method according to claim 6 , wherein the second therapeutic agent is bupivacaine free base.